Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing of PART1 knockdown by siRNA in ovarian cancer cells

ABSTRACT: RNA sequencing of PART1 knockdown by siRNA in ovarian cancer cells

PROVIDER: PRJNA1065835 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27589961_1.fastq.gz	Fastqsanger.gz
	SRR27589961_2.fastq.gz	Fastqsanger.gz
	SRR27589962_1.fastq.gz	Fastqsanger.gz
	SRR27589962_2.fastq.gz	Fastqsanger.gz
	SRR27589963_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

RNA sequencing of PART1 knockdown by siRNA in ovarian cancer cells

Project description:The expression of lncRNA PART1 was found to be significantly upregulated in platinum-sensitive patients with ovarian cancer, and this upregulation was positively correlated with a favorable prognosis. Cellular experiments demonstrated that inhibition of PART1 led to cellular senescence and increased resistance to cisplatin and PARP inhibitors. Thus, LncRNA PART1 is a novel target for overcoming resistance to PARP inhibitors in ovarian cancer.

2024-02-01 | GSE253450 | GEO

RNA sequencing of DDX23 knockdown by siRNA in ovarian cancer cells

Project description:RNA sequencing of DDX23 knockdown by siRNA in ovarian cancer cells

| PRJNA750648 | ENA

RNA sequencing of SF3B4 knockdown by siRNA in ovarian cancer cells

Project description:RNA sequencing of SF3B4 knockdown by siRNA in ovarian cancer cells

| PRJNA786621 | ENA

RNA sequencing of MEX3A knockdown by siRNA in ovarian cancer cells

Project description:RNA sequencing of MEX3A knockdown by siRNA in ovarian cancer cells

| PRJNA782974 | ENA

The effect of lncRNA PART1 knockdown on gene expression in HCC1806 and HCC1395 cells

Project description:PART1 was knocked down down using GapmeRs specific to PART1. The breast cancer cells used in this study were confirmed to have PART1 expression by qPCR and knockdown of PART was confirmed by qPCR.

2021-02-28 | GSE156114 | GEO

The effect of lncRNA PART1 knockdown on mature miRNA levels in HCC1806 and HCC1395 cells

2021-02-28 | GSE163569 | GEO

RNA sequencing (RNA-SEQ) of RECQL4 knockdown by siRNA in ovarian cancer cells

Project description:RNA sequencing (RNA-SEQ) of RECQL4 knockdown by siRNA in ovarian cancer cells

| PRJNA644339 | ENA

RNA sequencing (RNA-SEQ) of FOXM1 knockdown by siRNA in ovarian cancer cells

Project description:RNA sequencing (RNA-SEQ) of FOXM1 knockdown by siRNA in ovarian cancer cells

| PRJNA597472 | ENA

siRNA-mediated knockdown

Project description:siRNA-mediated knockdown

| PRJNA541912 | ENA

RNA sequencing (RNA-SEQ) of RECQL4 knockdown by siRNA in ovarian cancer cells

Project description:The high frequency of somatic copy number alterations, as opposed to point mutations, is considered a unique feature of high-grade serous ovarian carcinoma (HGSOC). Amplification-dependent overexpression of RECQL4, which participates in DNA replication and repair, mediates the development of various cancers, but its pathobiological and clinical roles are poorly understood. Here, using bioinformatics analysis, RECQL4 amplification was found to occur in 27% of HGSOC samples in the TCGA cohort. RECQL4 was found to be upregulated and associated with a poor prognosis based on the immunohistochemistry staining of HGSOC. Functionally, RECQL4 overexpression increased proliferation and invasion of ovarian cancer cells both in vitro and in vivo. RECQL4 silencing had the opposite effects. In addition, RECQL4 knockdown enhanced the sensitivity of ovarian cancer cells to cisplatin and PARP inhibitor (PARPi). Further mechanistic investigations revealed that MAFB was a downstream target of RECQL4. The oncogenic effect of RECQL4 was attenuated after MAFB knockdown. Moreover, RECQL4 overexpression was negatively regulated by the tumour suppressor miR-10a-5p. Collectively, these findings indicate that genomic amplification and low expression of miR-10a-5p contribute to RECQL4 overexpression in ovarian cancer. This is the first study to reveal the oncogenic functions and clinical significance of RECQL4 in ovarian cancer.

2020-10-13 | GSE153839 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data